CNTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

CNTX ▲ +1.29% at T+5d

NEUTRAL call ✓ call won +1.29% · α vs SPY -0.22% · entry $2.33 → $2.36

Next anchor: T+20d in 14d

Currently $2.32 · -0.64% from $2.33 entry

Entry anchored
May 6, 2026
via day open

T+1d

+2.15%

call +2.15% · α +1.32%

$2.38

settled 14d ago

T+5d

+1.29%

call +1.29% · α -0.22%

$2.36

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlighted upcoming clinical catalysts, including Phase 1a data for CTIM-76 in June 2026, while cash burn increased. Net loss widened to $8.7M vs $4.6M a year ago, with cash of $54.5M expected to fund operations into mid-2027.

Actionable Insight

Monitor upcoming CTIM-76 Phase 1a data in June 2026 and CT-95 data in September 2026 as primary catalysts. The EPS beat is modest given pre-revenue status; stock movement will likely hinge on clinical data rather than financials.

Key Facts

Q1 2026 EPS -$0.09 vs consensus -$0.12 (beat by $0.03, +25%)
Net loss $8.7M vs $4.6M in Q1 2025
Cash and equivalents $54.5M, down from $66.0M at year-end 2025
R&D expenses $7.0M, nearly doubled from $3.5M a year ago
FDA granted Fast Track Designation for CTIM-76 in April 2026
Phase 1a interim data for CTIM-76 expected June 2026; CT-95 data expected September 2026
CT-202 Phase 1 initiation expected Q3 2026

Financial Impact

EPS beat of $0.03 vs consensus; net loss increased to $8.7M from $4.6M

epscash burnr&d expenses

Risk Factors

Clinical trial failure for CTIM-76 or other pipeline candidates
Cash burn accelerated; may require dilutive financing if data readouts delay
No approved products; revenue growth not expected in near term

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

94% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3289410

5 reports for CNTX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CNTX — sortable, filterable
	Type				Now
May 18, 2026 3d ago	PRESS-RELEASE / 8-K BULLISH ★ 7/10	—	awaiting T+5	—	—
May 6, 2026 14d ago	Press Release MIXED ★ 5/10	$2.33 $2.36	▲ +1.29%	▼ −0.22%	$2.32 (−0.64%)
May 1, 2026 19d ago	8-K NEUTRAL ★ 2/10	$2.30 $2.39	▲ +3.91%	▲ +0.98%	$2.32 (+0.65%)
Apr 2, 2026 7w ago	8-K BULLISH ★ 7/10	$2.72 $2.49	▼ −8.46%	▼ −12.07%	$2.32 (−14.89%)
Mar 23, 2026 8w ago	Press Release MIXED ★ 5/10	$3.18 $2.62	▼ −17.61%	▼ −17.19%	$2.32 (−27.20%)

US Market Status

Market Open — Closes in 3h 52m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access